US Biomanufacturing Reshoring Policy Extends Relevance to Agrochemical Supply Chain Security

Introduction

The United States' growing focus on domestic biomanufacturing is primarily associated with pharmaceuticals, biotechnology, defense, and strategic materials. However, the same policy direction could eventually have implications for agrochemical supply chain security.

U.S. policy has increasingly emphasized expanding domestic biomanufacturing capacity, strengthening critical supply chains, reducing dependence on vulnerable foreign sources, and supporting biotechnology across agriculture and industrial applications. Executive Order 14081 specifically identified agriculture, supply-chain resilience, and national security among the areas where biotechnology and biomanufacturing should be advanced.

For agrochemical manufacturers, this creates a broader strategic question: could domestic biomanufacturing eventually provide alternative production routes for selected intermediates, active ingredients, or other agricultural inputs?

Why Biomanufacturing Reshoring Matters

Biomanufacturing offers an alternative approach to producing certain chemicals and materials traditionally manufactured through conventional petrochemical processes.

The U.S. government's earlier biotechnology strategy called for expanding domestic production capacity, increasing piloting and prototyping, supporting sustainable biomass production, and developing supply-chain resilience. It also specifically included agriculture and industrial sectors within the domestic biomanufacturing strategy.

More recent U.S. supply-chain policy has continued to emphasize reducing excessive dependence on concentrated foreign supply sources. A July 2026 executive order on critical materials, for example, highlighted risks associated with single suppliers, capacity constraints, disrupted deliveries, and over-reliance on foreign sources.

Although these policies are not specifically targeted at agrochemicals, their underlying principles are highly relevant to the agricultural chemicals industry.

The Connection to Agrochemical Supply Chains

Agrochemical manufacturing depends on a complex network of active ingredients, chemical intermediates, solvents, additives, and other inputs.

Many of these materials are produced through conventional chemical routes and may be concentrated in specific geographic regions.

This concentration can create vulnerabilities when supply chains are affected by:

• Geopolitical tensions

• Export restrictions

• Shipping disruptions

• Energy-price volatility

• Plant outages

• Raw-material shortages

• Concentration among a small number of suppliers

Domestic biomanufacturing could eventually provide an additional production pathway for selected molecules, helping reduce dependence on a single geographic or technological source.

From Pharmaceuticals to Agricultural Chemicals

The strongest current policy momentum for biomanufacturing reshoring is visible in pharmaceuticals.

For example, the U.S. government has pursued measures to increase domestic production of critical pharmaceutical inputs and reduce vulnerabilities associated with foreign supply concentration.

The technological infrastructure developed through these efforts could have wider applications.

Fermentation systems, engineered microorganisms, process-control technologies, bioreactors, downstream purification capabilities, and skilled workforces can potentially support production across multiple sectors.

This creates the possibility of technology spillovers from pharmaceutical and industrial biomanufacturing into agricultural chemicals.

Potential Applications in Agrochemicals

Not every agrochemical can be economically manufactured through biotechnology. However, biological production could become relevant for selected molecules and intermediates.

Potential areas include:

• Bio-based chemical intermediates

• Fermentation-derived active ingredients

• Specialty crop-protection compounds

• Renewable-carbon precursors

• Biological production of selected formulation materials

The strongest opportunities are likely to emerge where biological pathways can achieve competitive yields, reliable quality, and commercially attractive production costs.

Supply Security Could Become a Competitive Advantage

The biggest strategic benefit of domestic biomanufacturing may not necessarily be lower production costs.

Instead, it could be greater supply-chain resilience.

A domestic manufacturing route could provide U.S. agrochemical companies with an additional source of critical materials when overseas supply becomes disrupted.

This would allow procurement teams to move from a single-source or regionally concentrated model toward a more diversified portfolio.

In practical terms, a company could maintain conventional overseas suppliers while developing domestic biological production as a secondary or strategic source.

Biomass and Agricultural Feedstocks Add Another Dimension

Domestic biomanufacturing could also strengthen the connection between agriculture and industrial feedstock supply.

The 2022 U.S. biotechnology strategy included expanding sustainable biomass production and creating incentives for agricultural producers and forest landowners.

This creates a potential pathway in which agricultural resources—including sugars, starches, vegetable oils, and selected residues—become inputs for domestic chemical manufacturing.

Such integration could create additional markets for agricultural feedstocks while reducing reliance on imported fossil-derived raw materials.

However, the economics of collecting, processing, storing, and transporting biomass remain important constraints.

Cost and Scale Remain Major Challenges

Reshoring does not automatically mean cost competitiveness.

Domestic biomanufacturing facilities can require substantial capital investment, specialized infrastructure, skilled workers, regulatory approvals, and long development timelines. Industry analysis has noted that new biomanufacturing facilities can take years and require significant investment before becoming fully operational.

Agrochemical producers therefore cannot justify domestic biological production solely on the basis of supply security.

The technology must also demonstrate:

• Competitive production costs

• Reliable feedstock availability

• Consistent product quality

• Commercial-scale productivity

• Efficient downstream processing

• Regulatory acceptance

• Stable long-term operations

Implications for Agrochemical Procurement

The development could gradually change how procurement teams evaluate suppliers.

Instead of focusing exclusively on price and delivery, buyers may increasingly assess geographic production risk, technology pathway, feedstock security, domestic capacity, and alternative sourcing potential.

A supplier operating a domestic biological route could therefore provide strategic value even if its initial production cost is higher than an established imported alternative.

This could be particularly relevant for intermediates where supply concentration presents a greater risk than ordinary price volatility.

A Broader Shift Toward Supply-Chain Diversification

The objective of biomanufacturing reshoring is unlikely to be the complete replacement of global supply chains.

A more realistic outcome is a hybrid sourcing model.

U.S. manufacturers could continue using established international suppliers while gradually developing domestic production for strategically important materials.

This approach would provide redundancy without requiring companies to immediately abandon cost-efficient global production.

For agrochemical companies, such diversification could become increasingly attractive as governments place greater emphasis on supply-chain resilience.

What Agrochemical Companies Should Watch

Procurement and strategy teams should monitor several developments:

• U.S. funding for domestic biomanufacturing

• New fermentation and bioprocessing capacity

• Government incentives for bio-based production

• Development of domestic biomass supply chains

• Commercialization of bio-based chemical intermediates

• Partnerships between biotechnology companies and chemical manufacturers

• Policy measures targeting critical supply chains

• Cost reductions in industrial biotechnology

These indicators can help identify when biomanufacturing moves from a policy objective toward a commercially relevant sourcing option.

Outlook

US biomanufacturing reshoring is unlikely to transform agrochemical supply chains immediately. Conventional chemical production remains deeply established, while biological routes must overcome challenges related to cost, scale, infrastructure, and process reliability.

However, the strategic direction is significant.

Government efforts to build domestic biomanufacturing capacity are creating infrastructure, expertise, and investment that could eventually support applications beyond pharmaceuticals and defense. Because the U.S. biotechnology strategy already encompasses agriculture and industrial supply chains, agrochemicals could become part of this broader ecosystem.

Conclusion

The U.S. push toward biomanufacturing reshoring could eventually extend beyond pharmaceuticals and strategic materials to influence agrochemical supply chain security.

The most important impact may not be the immediate replacement of imported agrochemicals or intermediates. Instead, domestic biotechnology could provide alternative manufacturing pathways for strategically important products and reduce dependence on highly concentrated international supply chains.

For agrochemical companies, the strategic question is therefore shifting from whether domestic biomanufacturing can replace conventional chemistry to which products could benefit most from a diversified domestic biological production pathway.

As technology improves and domestic capacity expands, companies that identify these opportunities early could gain an advantage in supply security, sourcing flexibility, and long-term resilience.